
Daily Derm Times: August 15, 2025
Key Takeaways
- Biologic therapies like bimekizumab show promise in treating resistant acne conglobata, potentially improving patient outcomes.
- Synthetic data is revolutionizing CSU research, allowing for smaller sample sizes and more efficient, inclusive trials.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
Biologic Therapy Shows Promise for Tough Acne
Explore innovative acne therapies, including bimekizumab, offering hope for treatment-resistant acne conglobata and improved patient outcomes.
Data Innovation May Accelerate CSU Research
Explore how synthetic data revolutionizes CSU research, enabling smaller sample sizes and enhancing trial efficiency and inclusivity.
Virtual Therapy Shows Promise for Dermatological Body-Focused Repetitive Behaviors
Discover how internet-based therapy effectively treats dermatological BFRBs like trichotillomania and dermatillomania, enhancing patient outcomes and accessibility.
Uniting Experts and Advocates to Advance HS Care
A recent HS Summit hosted by UCB brought together clinicians and patient advocates to strengthen research and awareness efforts.
New Insights On the Link Between Comedogenic Cosmetics and Acne
The latest study reveals the link between cosmetic use and acne, highlighting the risks of comedogenic ingredients in moisturizers, facial cleansers, and powders.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















